Zentalis Pharmaceuticals, Inc.

ZNTL Healthcare Biotechnology

Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.13 0.11 −4.91%
Market cap
$212.1M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
n/a
Altman Z
−2.42
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
7.76 6.93 6.19 4.82
Net Debt/EBITDA
8.23 6.53 5.58 3.94
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.37) (0.43) (0.47) (0.52)
Book value per Share
3.51 3.01 2.60 2.01
Free Cash Flow
(26.96) (30.81) (32.99) (37.24)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates